BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma.
Xiao-Peng TianJun CaiShu-Yun MaYu FangHui-Qiang HuangTong-Yu LinHui-Lan RaoMei LiZhong-Jun XiaTie-Bang KangDan XieQing-Qing CaiPublished in: Cancer communications (London, England) (2020)
Our data showed that BRD2 promotes drug resistance in adult T-LBL through the RasGRP1/Ras/ERK signaling pathway. Targeting BRD2 may be a novel strategy to improve the therapeutic efficacy and prolong survival of adults with T-LBL.